Parotid small cell carcinoma presenting with long-term survival after surgery alone: a case report
© Kanazawa et al.; licensee BioMed Central Ltd. 2012
Received: 3 August 2012
Accepted: 14 November 2012
Published: 28 December 2012
Primary involvement of the salivary glands in small cell carcinoma is rare, and has one of the worst prognoses of salivary gland neoplasms. However, it has been reported that some cases have a favorable outcome, although the prognostic factors are still under consideration. Multidisciplinary therapy was usually required to achieve long-term survival. Recently, a resemblance of some small cell carcinomas of the salivary gland to cutaneous Merkel cell carcinoma was suggested; the latter have the potential for spontaneous regression, which is related to a favorable clinical outcome.
We present a locoregional advanced parotid small cell carcinoma with multiple lymph node metastases in an 87-year-old Asian woman. The tumor was controlled by surgery alone, and nine-year disease-free survival was achieved without any adjunctive therapy. To the best of our knowledge, this is the longest reported follow-up of head and neck small cell carcinoma.
We believe this to be the first case of small cell carcinoma with involvement of the salivary glands reported in the literature with a good outcome after surgery alone without any adjunctive therapy.
Primary involvement of the salivary glands in small cell carcinoma (SmCC) is rare, and tumors in the salivary glands account for less than 1% of all carcinomas of the parotid gland and 3.5% of all malignant tumors of minor salivary glands. This tumor has one of the worst prognoses of salivary gland neoplasms. The prognosis for patients with SmCC of the salivary glands has been reported to be more favorable than for those with SmCC of other sites [1–4]. However, there is no doubt that parotid SmCC is a high-grade malignancy that should be treated aggressively. Surgery, adjunctive radiation therapy and/or chemotherapy have been performed in most cases .
SmCCs of the salivary gland are classified into neuroendocrine types and ductal carcinomas. The neuroendocrine type can be classified further into Merkel-cell-like SmCC and pulmonary variants, based on cytokeratin 20 immunoreactivity with a dot-like staining pattern . Recently, the resemblance of Merkel-cell-like SmCCs of salivary gland to cutaneous Merkel cell carcinoma has been suggested, and some of them have spontaneous regression potential related to a favorable clinical outcome [1, 2]. In this article, we report a locoregional advanced parotid SmCC that had an unusual clinical course. The tumor was controlled by surgery alone, and nine-year disease-free survival was achieved without any adjunctive therapy. We also studied the expression of an oncogene or tumor suppressor gene, and demonstrated the expression of mammary serine protease inhibitor (Maspin), which is an important tumor suppressor gene of salivary gland carcinomas.
An 87-year-old Asian woman in good general health presented with a progressively enlarging mass located in her left preauricular region. Fine needle aspiration (FNA) cytology analysis performed in the clinic suggested malignant cells of uncertain origin, but the tumors showed a rapid and consistent regression after FNA. During six months of observation, the tumor regrew and the patient was referred to our hospital.
Our patient’s postoperative course was uneventful, and no postoperative radiotherapy was administered. The nine-year clinical follow-up, which is the longest follow-up of head and neck SmCC in our knowledge, revealed no locoregional recurrence or distant metastasis.
The parotid gland tumor in our case appeared on histology to be a SmCC. No tumor formation was recognized in other locations; therefore, this was an extremely rare primary SmCC of the parotid gland. This case also has the longest follow-up to the best of our knowledge. SmCC can occur in any organ, although the vast majority occur in the lung. The prognosis for patients with SmCC of the salivary glands has been reported to be more favorable than for those with SmCC of the lung or larynx [1, 2, 4]. However, there is no doubt that parotid SmCC is a high-grade malignancy that should be treated aggressively. The main treatment for parotid SmCC is a surgical approach with partial or total parotidectomy. The association of radiotherapy with surgery has shown a decrease in relapses and an increase in survival. Seventy-five percent of local relapses occurred in cases where surgery had been the only treatment, whereas, when associated with radiotherapy, the rate of local relapse was 20% [1, 5]. Our case was controlled by surgery alone, and nine-year disease-free survival was achieved without any adjunctive therapy despite the advanced nature of the disease.
Recently, two parotid SmCCs with unusual clinical courses were reported. Mulder et al. presented a primary SmCC of the parotid with massive local recurrence that regressed spontaneously . Jorcano et al. also presented an advanced case where a complete response and long-term survival was achieved by radiotherapy alone . Both cases involved Merkel-cell-like SmCC. The neuroendocrine type of SmCC can be subdivided into Merkel-cell-like and pulmonary varieties on the basis of cytokeratin 20 immunoreactivity with a dot-like staining pattern . It has been speculated that some salivary Merkel-cell-like SmCC are closely related biologically to cutaneous Merkel cell carcinoma, which is known to be less aggressive than extrasalivary SmCC . One possibility for a favorable clinical outcome after initial treatment is the potential for spontaneous regression. We could find one only case of spontaneous regression of a salivary Merkel-cell-like SmCC , but spontaneous regression of cutaneous Merkel cell carcinomas has been described in 20 cases [9, 10]. Furthermore, 10% to 20% of all cases of metastasized cutaneous Merkel cell carcinomas present no obvious primary tumor . It is not known if the primary lesion had regressed in these cases. The reasons for spontaneous regression remain unclear. Mulder et al. explained the mechanism of spontaneous regression as follows: “apoptotic events seem to play an important part, and a local T-cell mediated immune response triggered by surgical trauma might also be involved”. The hypothesis that spontaneous regression occurs after surgery might help understand this unusual clinical course. The fact that spontaneous regression was observed after initial FNA also supports this hypothesis in our case.
To understand the mechanism of spontaneous regression further, we studied the expressions of various oncogenes or tumor suppressor genes, and demonstrated the expression of Maspin. Maspin belongs to the serine protease inhibitor family and may be associated with a favorable prognosis in common salivary gland carcinomas such as adenoid cystic carcinoma, mucoepidermoid carcinoma and carcinoma ex pleomorphic adenoma . Although Maspin expression in salivary SmCC might be important information, the relationship between Maspin and spontaneous regression is under consideration.
The mechanism of spontaneous regression in salivary SmCC is not fully understood, but our experience with this case leads us to suggest that some cases have a favorable clinical outcome that is related to the potential for spontaneous regression.
Written informed consent was obtained from the patient’s guardian for publication of this case report. A copy of the written consent is available for review by the Editor-in-Chief of this journal.
- Gnepp DR, Corio RL, Brannon RB: Small cell carcinoma of the major salivary glands. Cancer. 1986, 58: 705-714. 10.1002/1097-0142(19860801)58:3<705::AID-CNCR2820580318>3.0.CO;2-T.View ArticlePubMedGoogle Scholar
- Nagao T, Gaffey TA, Olsen KD, Serizawa H, Lewis JE: Small cell carcinoma of the major salivary glands: clinicopathologic study with emphasis on cytokeratin 20 immunoreactivity and clinical outcome. Am J Surg Pathol. 2004, 28: 762-770. 10.1097/01.pas.0000126776.65815.48.View ArticlePubMedGoogle Scholar
- Hui KK, Luna MA, Batsakis JG, Ordonez NG, Weber R: Undifferentiated carcinomas of the major salivary glands. Oral Surg Oral Med Oral Pathol. 1990, 69: 76-83. 10.1016/0030-4220(90)90271-S.View ArticlePubMedGoogle Scholar
- Pierce ST, Cibull ML, Metcalfe MS, Sloan D: Bone marrow metastases from small cell cancer of the head and neck. Head Neck. 1994, 16: 266-271. 10.1002/hed.2880160310.View ArticlePubMedGoogle Scholar
- Jorcano S, Casado A, Berenguer J, Arenas M, Rovirosa A, Colomo L: Primary neuroendocrine small cell undifferentiated carcinoma of the parotid gland. Clin Transl Oncol. 2008, 10: 303-306. 10.1007/s12094-008-0203-z.View ArticlePubMedGoogle Scholar
- Mulder DC, Rosenberg AJ, Storm-Bogaard PW, Koole R: Spontaneous regression of advanced merkel-cell-like small cell carcinoma of the parotid gland. Br J Oral Maxillofac Surg. 2010, 48: 199-200. 10.1016/j.bjoms.2009.06.008.View ArticlePubMedGoogle Scholar
- Chan JK, Suster S, Wenig BM, Tsang WY, Chan JB, Lau AL: Cytokeratin 20 immunoreactivity distinguishes Merkel cell (primary cutaneous neuroendocrine) carcinomas and salivary gland small cell carcinomas from small cell carcinomas of various sites. Am J Surg Pathol. 1997, 21: 226-234. 10.1097/00000478-199702000-00014.View ArticlePubMedGoogle Scholar
- Mills SE: Neuroectodermal neoplasms of the head and neck with emphasis on neuroendocrine carcinomas. Mod Pathol. 2002, 15: 264-278. 10.1038/modpathol.3880522.View ArticlePubMedGoogle Scholar
- Richetta AG, Mancini M, Torroni A, Lore B, Iannetti G, Sardella B, Calvieri S: Total spontaneous regression of advanced Merkel cell carcinoma after biopsy: review and a new case. Dermatol Surg. 2008, 34: 815-822. 10.1111/j.1524-4725.2008.34153.x.PubMedGoogle Scholar
- Vesely MJ, Murray DJ, Neligan PC, Novak CB, Gullane PJ, Ghazarian D: Complete spontaneous regression in Merkel cell carcinoma. J Plast Reconstr Aesthet Surg. 2008, 61: 165-171. 10.1016/j.bjps.2006.10.020.View ArticlePubMedGoogle Scholar
- Schwarz S, Ettl T, Kleinsasser N, Hartmann A, Reichert TE, Driemel O: Loss of Maspin expression is a negative prognostic factor in common salivary gland tumors. Oral Oncol. 2008, 44: 563-570. 10.1016/j.oraloncology.2007.07.004.View ArticlePubMedGoogle Scholar
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.